Interaction between tacrolimus and nefazodone in a stable renal transplant recipient

Pharmacotherapy

Volumn 18, Issue 6 I, 1998, Pages 1356-1359

  Olyaei, Ali J ^a   DeMattos, Angelo M ^a   Norman, Douglas J ^a   Bennett, William M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; AZATHIOPRINE; BICARBONATE; CALCIUM CARBONATE; CARBAMAZEPINE; CIMETIDINE; CLARITHROMYCIN; CYCLOSPORIN; CYCLOSPORIN A; DILTIAZEM; ERYTHROMYCIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; METHYLPREDNISOLONE; MEVINOLIN; MIBEFRADIL; NEFAZODONE; NICARDIPINE; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; TACROLIMUS; VERAPAMIL;

ADULT; ARTICLE; CASE REPORT; DEPRESSION; DRUG METABOLISM; DRUG MONITORING; FEMALE; FOOD DRUG INTERACTION; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CONFUSION; DEPRESSION; DRUG INTERACTIONS; FEMALE; HEADACHE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MIDDLE AGED; TACROLIMUS; TRIAZOLES; VISION DISORDERS;

EID: 0031785653     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Seifeldin R. Drug interactions in transplantation. Clin Ther 1995;17:1043-61.
2. Campana C, Regazzi MB, Buggia I, Molinaro M. Clinically significant drug interactions with cyclosporin. An update. Clin Pharmacokinet 1996;30:141-79.
3. Mignat C. Clinically significant drug interactions with new immunosuppressive agents. Drug Saf 1997;16:267-78.
4. Kelly PA, Burckart GJ, Venkataramanan R. Tacrolimus: a new immuosuppressive agent. Am J Health-Syst Pharm 1995;52: 1521-35.
5. Pratschke J, Neuhaus R, Tullius SG, et al. Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation. Transplantation 1997;64:938-40.
6. Morris-Stiff G, Jurewicz A, Balaji V, et al. Conversion from cyclosporin to tacrolimus in a patient with prolonged acute tubular necrosis. Transplant Int 1997;10:398-400.
7. Sher LS, Cosenza CA, Michel J, et al. Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation: a report of the U.S. multicenter liver study group. Transplantation 1997;64:258-63.
8. Dodd DA. Rapid resolution of gingival hyperplasia after switching from cyclosporine A to tacrolimus [letter]. J Heart Lung Transplant 1997;16:579.
9. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995;29:404-30.
10. Winkler M, Christians U. A risk-benefit assessment of tacrolimus in transplantation. Drug Saf 1995;12:348-57.
11. Matsuda H, Iwasaki K, Shiraga T, Tozuka Z, Hata T, Guengerich FP. Interactions of FK506 (tacrolimus) with clinically important drugs. Mol Pathol Pharmacol 1996;91:57-64.
12. Spencer CM, Goa KL, Gillis JC. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997;54:925-75.
13. Shihab FS, Bennett WM, Tanner AM, Andoh TF. Mechanism of fibrosis in experimental tacrolimus nephrotoxicity. Transplantation 1997;64:1829-37.
14. Andoh TF, Burdmann EA, Bennett WM. Nephrotoxicity of immunosuppressive drugs: experimental and clinical observations. Semin Nephrol 1997;17:34-45.
15. de Mattos AM, Olyaei AJ, Bennett WM. Pharmacology of immunosuppressive medications used in renal diseases and transplantation. Am J Kidney Dis 1996;28:631-67.
16. Clark W. Tacrolimus:immunosuppression following liver and kidney transplant. J Clin Pharm Ther 1996;21:135-41.
17. McMaster P, Mirza DF, Ismail T, Vennarecci G, Patapis P, Mayer AD. Therapeutic drug monitoring of tacrolimus in clinical transplantation. Ther Drug Monit 1995;17:602-5.
18. Riesenman C. Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal. Pharmacotherapy 1995;15(2, pt 2):84S-99.
19. Ereshefsky L, Riesenman C, Lam YW. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. Clin Pharmacokinet 1995;29(suppl 1):108.
20. von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI. Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology. Clin Pharmacokinet 1995;29(suppl 1):33-43.
21. First MR, Schroeder TJ, Michael A, Hariharan Sl, Weiskittel P, Alexander JW. Cyclosporine-ketoconazole interaction. Long-term follow-up and preliminary results of a randomized trial. Transplantation 1993;55:1000-4.
22. Rossi SJ, Schroeder TJ, Hariharan S, First MR. Prevention and management of the adverse effects associated with immunosuppressive therapy. Drug Saf 1993;9:104-31.
23. Lake KD, Canafax DM. Important interactions of drugs with immunosuppressive agents used in transplant recipients. J Antimicrob Chemother 1995;36(suppl B):11-22.
24. Kennedy DT, Hayney MS, Lake KD. Azathioprine and allopurinol: the price of an avoidable drug interaction. Ann Pharmacother 1996;30:951-4.
25. Bristol-Myers Squibb. Serzone (nefazodone) package insert. Princeton NJ;1996.